Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suzetrigine Pharmacodynamics in Healthy Male Adults
NCT06972212Phase 1Completed
- Sponsor
- Latigo Biotherapeutics
- Start
- Jun 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of suzetrigine in acute pain (2 arms), sponsored by Latigo Biotherapeutics. Primary endpoints: Change from baseline pain score, Time to reach Pain Detection Threshold and 1 more. Started Jun 2025; status: completed.
02
Drugs
suzetrigine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT06972212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972212.